• 020 7251 3322
  • 1st Floor Citibase Millbank Tower, 21-24 Millbank, London SW1P 4QP

Fremanezumab (AJOVY®) now available within NHS Scotland

13 January 2020

The Scottish Medicines Consortium (SMC) announced today that fremanezumab (Ajovy®) has been accepted for a restricted use within NHS Scotland for the prevention of migraine in adults who have at least four migraine days per month.

We welcome this news and Dr David Bloomfield CEO of National Migraine Centre said: ”We are pleased that the SMC have approved Ajovy and migraine patients in Scotland now have access to another treatment option. We hope that NICE may approve one of the new treatment options soon to provide universal access to modern preventatives. ”

At the National Migraine Centre we have been treating patients with Ajovy for sometime now and are pleased with the results. Our Headache Specialist, Dr Katy Munro said ‘The new injections for prevention of migraine which target the CGRP neuro-chemical pathway have been extremely useful additions to the therapies available to us at the National Migraine Centre. We are delighted to hear of the decision to approve this in Scotland but would be more delighted if these drugs were also available in England, Wales and Northern Ireland. Many patients lives can be greatly improved and the severe impact of migraine lessened by finding the right treatment for their condition. These need to be included in the range of options available.’ Dr Jessica Briscoe, Headache Specialist, also said ‘I am delighted to hear that Scotland have agreed to allow another new treatment for migraine to be funded by the NHS. It has been shown to be an effective and well tolerated treatment in those we have prescribed it for so far and I am hopeful that this will encourage NICE to allow this and similar treatments to be funded by the NHS.’

What is Ajovy?

Ajovy is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults. Ajovy is an injectable prescription medicine, which can be self-administered.

What is the restricted criteria?

The drug may be used in patients that have at least four migraine days per month who have failed to respond to at least three other preventative treatments.

What does this mean for you ?

If you live in Scotland and have migraines at least four day per month and have failed three other preventative treatments then you could be eligible to be able to access Ajovy on the NHS.

People who qualify under the restricted criteria laid out by NHS Scotland should speak to their healthcare professional. If their healthcare professional thinks that Ajovy is the right medicine for you, then you should be able to have that treatment on the NHS.

For more information click here or call us on 020 7251 3322.

At NMC our headache specialists can  prescribe Ajovy privately until it is available on the NHS across the UK. Book Now!